Plant Name: Coreopsis nodosa
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| ADORA3; ADORA2A; ADORA1; FFAR1; FFAR4; HCAR2; | |
| CTDSP1; TDP1; RECQL; ADK; HPGD; HSD17B1; AKR1B1; HSD17B2; NOX4; ALOX15; IDE; POLB; | |
| GAA; | |
| DAPK1; FLT3; | |
| CA2; CA12; CA7; | |
| AR; | |
| PPARA; PPARD; PPARG; | |
| ESRRA; | |
| ALOX5; TYR; XDH; | |
| TLR2; | |
| AHR; HIF1A; TP53; STAT6; | |
| ABCG2; ABCC1; | |
| SLC28A2; SLC28A3; SLC28A1; | |
| LMNA; FABP5; FABP2; FABP4; FABP3; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | IDE | Insulin-degrading enzyme | P14735 | CHEMBL1293287 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.872E-11 | 9.369E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.053E-09 | 2.557E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.009E-09 | 2.557E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, NOX4 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 5.121E-09 | 3.797E-06 | AHR, AR, ESRRA, PPARA, PPARD, PPARG |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.627E-08 | 9.574E-06 | ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, XDH |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 2.977E-08 | 1.639E-05 | AKR1B1, AR, CA2, CYP1A2, ESRRA, FABP3, FFAR4, FLT3, HPGD, PPARA, PPARG, TLR2, TSHR |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 3.396E-07 | 1.369E-04 | CYP1A1, POLB, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 4.343E-07 | 1.550E-04 | ALOX15, ALOX5, HPGD |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.343E-07 | 1.550E-04 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 6.920E-07 | 2.249E-04 | AR, ESRRA, PPARA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 7.117E-07 | 2.279E-04 | FABP2, FABP3, FABP4, FABP5 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 7.584E-07 | 2.294E-04 | ADORA1, ADORA2A, ADORA3 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.672E-06 | 4.234E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, NOX4 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 1.748E-06 | 4.277E-04 | ABCC1, ALOX15, ALOX5, TLR2 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 1.813E-06 | 4.298E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0032502; developmental process | GO:0048513; animal organ development | 4.219E-06 | 9.007E-04 | AR, CA2, CYP1A1, CYP1A2, ESRRA, FLT3, HIF1A, HPGD, HSD17B2, POLB, PPARA, PPARD, PPARG, TYR |
| MF | Unclassified; | GO:0004872; receptor activity | 4.179E-06 | 9.007E-04 | ADORA1, ADORA2A, ADORA3, AHR, AR, ESRRA, FFAR1, FFAR4, FLT3, HCAR2, HPGD, PPARA, PPARD, PPARG, TLR2, TSHR |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.719E-06 | 9.977E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:1901652; response to peptide | 6.089E-06 | 1.223E-03 | AKR1B1, FABP3, FFAR4, PPARA, PPARG, TLR2, TP53, TSHR |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 6.123E-06 | 1.223E-03 | ADORA2A, CA2, CA7 |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 7.961E-06 | 1.469E-03 | SLC28A2, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 7.961E-06 | 1.469E-03 | SLC28A1, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 7.961E-06 | 1.469E-03 | SLC28A2, SLC28A3 |
| BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 8.630E-06 | 1.540E-03 | ADORA1, ADORA2A, PPARA, PPARG, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 9.701E-06 | 1.690E-03 | CA12, CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 1.018E-05 | 1.750E-03 | AHR, AR, ESRRA, PPARA, PPARD, PPARG |
| MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 1.021E-05 | 1.750E-03 | ADORA1, ADORA2A, AHR, HIF1A, PPARD, PPARG, TLR2, TP53, TYR |
| BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 1.119E-05 | 1.890E-03 | ABCG2, AKR1B1, CA12, CA2, CA7, FABP3, FABP4, FFAR1, HIF1A, NOX4, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.192E-05 | 1.981E-03 | ALOX15, ALOX5, HPGD |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 1.444E-05 | 2.329E-03 | CYP1A1, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0031000; response to caffeine | 1.729E-05 | 2.690E-03 | ADORA2A, PPARG, TP53 |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 2.384E-05 | 3.460E-03 | SLC28A1, SLC28A3 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.384E-05 | 3.460E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 2.384E-05 | 3.460E-03 | SLC28A1, SLC28A3 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 2.384E-05 | 3.460E-03 | ADORA1, ADORA2A |
| BP | GO:0023052; signaling | GO:0046887; positive regulation of hormone secretion | 2.812E-05 | 4.002E-03 | ADORA2A, FFAR1, HCAR2, HIF1A, PPARD |
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 3.226E-05 | 4.474E-03 | ALOX15, CA2, CYP1A1, CYP1A2, FABP4, HIF1A, TP53 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 3.395E-05 | 4.679E-03 | AR, ESRRA, PPARA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 3.716E-05 | 4.994E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.716E-05 | 4.994E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 3.947E-05 | 5.240E-03 | FABP3, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 4.238E-05 | 5.493E-03 | CYP1A1, CYP1A2, PPARG |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.759E-05 | 5.980E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 4.806E-05 | 5.980E-03 | HIF1A, PPARD, TP53 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.759E-05 | 5.980E-03 | CYP1A2, CYP2C9 |
| BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 4.987E-05 | 6.170E-03 | ADORA2A, CYP1B1, DAPK1, HCAR2, HPGD, NOX4, PPARG, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0045937; positive regulation of phosphate metabolic process | 5.144E-05 | 6.293E-03 | ADORA1, ADORA2A, ALOX15, AR, FABP3, FFAR4, FLT3, HIF1A, NOX4, TP53, TSHR, XDH |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 5.359E-05 | 6.509E-03 | ADORA2A, FFAR1, HCAR2, HIF1A, PPARD, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 6.823E-05 | 7.902E-03 | ALOX15, PPARA, PPARD, TP53 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 7.917E-05 | 8.893E-03 | PPARA, PPARG |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 7.923E-05 | 8.893E-03 | FABP3, FFAR1, PPARG, TLR2 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 8.642E-05 | 9.601E-03 | AR, CA12, CA2, CA7, ESRRA, IDE, PPARA, PPARD, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 9.122E-05 | 9.981E-03 | AR, ESRRA, PPARA, PPARD, PPARG |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 7.575E-10 | 8.711E-08 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.518E-07 | 1.448E-05 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 5.355E-07 | 2.053E-05 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.155E-06 | 3.320E-05 | CYP2C9; CYP1A2; ALOX15; CYP2C19 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.033E-06 | 6.976E-05 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP2C19 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.341E-05 | 3.646E-04 | GAA; ALOX15; ADK; AKR1B1; CYP2C19; TYR; CYP2C9; HSD17B1; ALOX5; HSD17B2; CYP1A2; CYP1A1; XDH |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.536E-05 | 3.646E-04 | CYP2C9; ALOX5; ALOX15; CYP2C19 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.029E-04 | 1.075E-03 | AR; FLT3; DAPK1; PPARG; HIF1A; TP53; PPARD |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.839E-05 | 6.183E-04 | CYP2C9; CYP1A2; CYP1A1; CYP1B1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.154E-04 | 1.906E-03 | HCAR2; ADORA2A; ADORA1; PPARA; TSHR |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.551E-04 | 2.095E-03 | CYP2C9; ALOX5; ALOX15; CYP2C19 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.809E-04 | 1.734E-03 | CYP1A2; CYP1A1; CYP1B1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 3.319E-04 | 2.545E-03 | ABCC1; ADORA3; ADORA1; TP53 |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.302E-05 | 2.496E-04 | CA12; CA2; CA7 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 4.920E-04 | 3.536E-03 | FABP4; ADORA1; TSHR |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 8.323E-04 | 5.318E-03 | FLT3; TP53; HIF1A |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 7.619E-04 | 5.154E-03 | CYP2C9; CYP1A2; CYP1A1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 9.068E-04 | 5.488E-03 | CYP2C9; CYP1A2; CYP2C19 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.513E-03 | 8.700E-03 | HPGD; FLT3; PPARG; TP53 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 7.059E-03 | 3.247E-02 | ADORA2A; ADORA3; ADORA1; TSHR |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 7.577E-03 | 3.351E-02 | STAT6; TP53; TLR2 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.076E-02 | 4.582E-02 | FLT3; PPARD |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 5.684E-03 | 2.842E-02 | DAPK1; TP53 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 2.874E-03 | 1.574E-02 | PPARG; TP53 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 6.523E-03 | 3.126E-02 | ABCC1; ABCG2 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 3.074E-03 | 1.607E-02 | GAA; AKR1B1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 7.386E-05 | 8.494E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; ADORA3; HIF1A; TP53; FLT3; FLT3; TLR2 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| NA: NA | Edema | NA | CA2 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; TLR2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PPARG; PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; ESRRA |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| H00-H59: Diseases of the eye and adnexa | Retinitis pigmentosa | H35.5 | IDE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; TYR; AKR1B1; ESRRA |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; FLT3; FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; FLT3; TLR2 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; PPARD; HCAR2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; ABCC1; ESRRA |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; ADORA2A; ADORA1; ESRRA |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; HCAR2 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; PPARD; HCAR2; PPARG; PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; ESRRA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; ADORA1; XDH |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA2A; ADORA1 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| C00-D49: Neoplasms | Melanoma | C43 | TYR; TLR2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ADORA2A; ADORA1 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; ADORA2A; ADORA1; AKR1B1 |
| NA: NA | GIST | NA | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; ABCC1; ABCC1; PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; HCAR2 |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
| NA: NA | Male hypogonadism | NA | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HCAR2 |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | PPARG |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; PPARD; HCAR2 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; ADORA2A |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Skin infections | L00-L99 | IDE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; FFAR1; AKR1B1; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| NA: NA | HIV infections | NA | AHR |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; ADORA2A; ADK |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; ADORA3 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; ESRRA |